CUMBERLAND PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $36.0M |
| Cost of revenue | $6.7M | $6.6M | $6.1M | $9.1M | $8.8M |
| Research and development | $5.6M | $4.8M | $5.8M | $6.7M | $5.7M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M |
| Interest expense | $495,990 | $605,508 | $667,861 | $585,995 | $98,031 |
| Pretax income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$5.6M |
| Income tax expense | $40,256 | -$22,669 | $45,769 | $68,850 | $34,891 |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M |
| Balance Sheet | |||||
| Cash and equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M |
| Current assets | $37.1M | $36.5M | $35.7M | $45.9M | $45.7M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Current liabilities | $36.7M | $31.6M | $28.0M | $28.6M | $19.3M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M |
| Stockholders' equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M |
| Cash Flow Statement | |||||
| Cash from operations | $4.9M | -$612,186 | $6.1M | $8.5M | $6.3M |
| Depreciation and amortization | $4.1M | $4.9M | $4.9M | $5.3M | $4.6M |
| Stock-based compensation | $408,320 | $301,895 | $365,040 | $447,503 | $741,867 |
| Capital expenditure | $97,903 | $66,461 | $281,268 | $102,148 | $103,532 |
| Free cash flow | $4.8M | -$678,647 | $5.8M | $8.4M | $6.2M |
| Share repurchases | $263,478 | $579,049 | $740,533 | $1.1M | $1.4M |
| Impairments | — | $400,000 | $0 | $0 | $0 |
Shares outstanding 15.0M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.